Zoek in het archief
 
terug

Check the original
News breaking: 2018-01-04

Teva to Present at the 36th Annual J.P. Morgan Healthcare Conference


Previous Article
Teva Announces Launch of an Authorized...
Teva to Present at the 36th Annual J.P. Morgan Healthcare Conference
JERUSALEM--(BUSINESS WIRE)--Jan. 4, 2018--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the 36th Annual J.P. Morgan Healthcare Conference.
Kåre Schultz, President & CEO will present on Monday, January 8, 2018 at
9:30 AM PST.
What:
 
Teva Presentation at the 36th Annual J.P. Morgan
Healthcare Conference
 
Who:
Kåre Schultz, President & CEO
Teva Pharmaceutical Industries Ltd.
 
When:
Monday, January 8, 2018 at 9:30 AM PST
 
Where:
www.ir.tevapharm.com
 
How:
Live over the Internet – log on to the Web at the address above and
register for the event (approximately 10 minutes before). An archive
of the webcast will be available on Teva’s website.
 
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in over 60 markets every day. Headquartered in Israel, Teva is
the world’s largest generic medicines producer, leveraging its portfolio
of more than 1,800 molecules to produce a wide range of generic products
in nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva’s net revenues in 2016 were $21.9 billion. For more information,
visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005883/en/
Source: Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.IR:United States:Kevin
C. Mannix, 215-591-8912orIsrael:Ran Meir, 972 (3)
926-7516orIsrael:Tomer Amitai, 972 (3) 926-7656orPR:Israel:Iris
Beck Codner, 972 (3) 926-7208orUnited States:Denise
Bradley, 215-591-8974
Share on FacebookShare on LinkedIn